Alzamend Neuro (ALZN) Liabilities and Shareholders Equity (2020 - 2026)

Alzamend Neuro has disclosed Liabilities and Shareholders Equity across 7 years of filings, most recently posting $2.1 million for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity fell 54.83% year-over-year to $2.1 million; the TTM figure through Apr 2026 stood at $17.5 million (up 13.48% YoY), while the FY2026 annual figure was $2.1 million, down 54.83% from the prior year.
• Liabilities and Shareholders Equity came in at $2.1 million for Q2 2026 at Alzamend Neuro, down from $4.0 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $14.5 million in Q2 2022 to a low of $631588.0 in Q2 2024.
• Average Liabilities and Shareholders Equity over 5 years is $5.7 million, with a median of $4.8 million recorded in 2024.
• Year-over-year, Liabilities and Shareholders Equity plunged 90.79% in 2024 and jumped 628.8% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $10.4 million in 2022, then plunged by 90.56% to $983597.0 in 2023, then soared by 409.12% to $5.0 million in 2024, then grew by 1.68% to $5.1 million in 2025, then tumbled by 59.16% to $2.1 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $2.1 million in Q2 2026, $4.0 million in Q1 2026, and $5.1 million in Q4 2025.